Crispr/cas9-mediated pd-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor t cells

HIGHLIGHTS

• who: Levi J. Rupp from the Department of Cellular and Molecular Pharmacology, San Francisco, CA, USA Center for Systems and Synthetic Biology, University of California San Francisco, San Francisco, CA, USA. Helen Diller Family Comprehensive have published the Article: CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells, in the Journal: Scientific Reports Scientific Reports of 20/04/2016
• what: The authors show that programmed death ligand 1 (PD-L1) expression on tumor cells can render human CAR T cells (anti-CD19 4-1BBζ) hypo-functional resulting . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.